Glenda Gray, MBBCH, FCPaed(SA), DSc (honoris causa), is the President & CEO of the South African Medical Research Council . She is a Research Professor of Paediatrics at the University of the Witwatersrand, and a director at the Perinatal HIV Research Unit in Soweto. Trained as a paediatrician, she was awarded a Fogarty Training Fellowship at Columbia University in 1999 and also completed an intensive program on clinical epidemiology at Cornell University. Based in South Africa, she is the Co-PI of the HVTN and Director of HVTN Africa Programs. She is a member of the Vaccine and Infectious Disease Division at the Fred Hutch. She has expertise in the field of mother to child transmission of HIV, adolescent HIV prevention and treatment, and HIV vaccine and microbicide research.
She received the Femina "Woman of the Nineties" Award, for her contribution to Perinatal HIV Research. In 2002, together with James McIntyre, she was awarded the Nelson Mandela Health and Human Rights Award for pioneering work done in the field of Mother-to-Child Transmission of HIV-1. Glenda was awarded the IAPAC "Hero of Medicine" award for work done in the field of HIV treatment in children and adults. In 2009, together with James McIntyre she received the N'Galy-Mann lectureship at CROI in recognition of their HIV research contribution in South Africa. She is a member of the Academy of Science in South Africa, Chair of their Standing Committee on Health and has served on a number of expert panels for the Academy in the field of infant health, nutrition and HIV. She was elected as a foreign associate into the US Institute of Medicine of the National Academy of Sciences and serves on their Board of Global Health. She is also a Fellow of the American Academy of Microbiology. She serves on IAVI’s Scientific Advisory Committee, and is a member of the Scripps CHAVI-ID Scientific Advisory Board. In 2013, she received the Order of Mapungubwe, South Africa’s highest honor, for achievements in the international arena which have served South Africa's interests. In the same year she received the EDCTP Outstanding African Scientist award.
Glenda became involved in HIV Vaccine research in 2000, and led the first clinical trials involving HIV vaccines in the Republic of South Africa (RSA). She was the Protocol Chair for the first phase 2B HIV vaccine trial to be conducted in sub-Saharan Africa, and was in charge of the early clinical development of South Africa's first two candidate DNA and MVA HIV vaccines, which have been tested in both the USA and RSA under FDA and MCC regulations. She was the International Vice Chair for Vaccines for the NIH-funded IMPAACT network until 2010. She has published extensively in the field of HIV.